Physician profile
James Glenn Botts
NPI 1700827995
$1,290.59
in general payments reported to CMS, 2019-2025
22 companies · $187 in 2025
The $187 reported for 2025 was more than what 75% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $39.34 · 2021: $42.02 · 2022: $275 · 2023: $297 · 2024: $267 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $190.33 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $175.17 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $122.83 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $110.78 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.59 | 2019-2024 | Jardiance |
| Abbvie INC. | $84.28 | 2022-2023 | Dalvance |
| Shionogi INC | $75.48 | 2022-2024 | Fetroja |
| Stryker Corporation | $64.69 | 2025 | Flowtriever |
| Recor Medical INC | $58.43 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Abbott Laboratories | $44.41 | 2023-2025 | Freestyle Libre 3, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $27.58 | 2022-2024 | Lokelma |
| Boston Scientific Corporation | $27.20 | 2024 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $27.02 | 2021-2022 | |
| Melinta Therapeutics, LLC | $25.92 | 2019 | |
| Daiichi Sankyo INC. | $25.90 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.07 | 2025 | Xifaxan |
| Atricure, INC. | $21.99 | 2024 | |
| Abiomed | $21.86 | 2025 | |
| Gilead Sciences, INC. | $20.06 | 2023 | |
| Smith+Nephew, INC. | $18.14 | 2025 | Collagenase Santyl |
| Otsuka America Pharmaceutical, INC. | $13.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Botts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.